Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

ClinicalTrials.gov ID: NCT03289273

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03289273. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

REFINE: Regorafenib Observational Study in Hepatocellular Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)

Study identification

NCT ID: NCT03289273
Recruitment status: Completed
Study type: Observational
Phase: Not listed
Lead sponsor: Bayer; Industry
Enrollment: 1,010 participants

Conditions and interventions

Conditions

Liver Neoplasms

Interventions

Regorafenib (Stivarga, BAY73-4506) Drug

Drug

Eligibility (public fields only)

Age range: Not listed
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 13, 2017 (Actual)
Primary completion: Jan 31, 2022 (Actual)
Completion: Jun 21, 2022 (Actual)
Last update posted: Jun 13, 2023

2017 – 2022

United States locations

U.S. sites: 17
U.S. states: 12
U.S. cities: 16

Facility	City	State	ZIP	Site status
Banner MD Anderson Cancer Center	Gilbert	Arizona	85234	—
St. Joseph´s Hospital and Medical Center	Phoenix	Arizona	85013	—
University of Florida Health	Gainesville	Florida	32610	—
University of Louisville - Clinical Trials Unit	Louisville	Kentucky	40202	—
University Medical Center	New Orleans	Louisiana	70112	—
Mercy Medical Center	Baltimore	Maryland	21202	—
University of Michigan	Ann Arbor	Michigan	48109	—
Henry Ford Health System	Detroit	Michigan	48202	—
Mayo Clinic	Rochester	Minnesota	55905	—
Rutgers University	Newark	New Jersey	07101-1709	—
Roswell Park Cancer Institute	Buffalo	New York	14263	—
C.R.Wood Cancer Center, Glen Falls Hospital	Glens Falls	New York	12801	—
University of Cincinatti	Cincinnati	Ohio	45267	—
Corporal Michael J. Crescenz VA Medical Center	Philadelphia	Pennsylvania	19104	—
Einstein Medical Center	Philadelphia	Pennsylvania	19141	—
UT Southwestern Medical Center	Dallas	Texas	75390	—
MD Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03289273, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 13, 2023 · Synced Nov 15, 2026